Plasma Sex Steroid Hormone Levels and Risk of Breast Cancer in Postmenopausal Women
Open Access
- 2 September 1998
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 90 (17) , 1292-1299
- https://doi.org/10.1093/jnci/90.17.1292
Abstract
Background: A positive relationship has generally been observed between plasma estrogen levels and breast cancer risk in postmenopausal women, but most of these studies have been small and few have evaluated specific estrogen fractions (such as percent bioavailable estradiol). In addition, few studies have evaluated plasma androgen levels in relation to breast cancer risk, and their results have been inconsistent. We prospectively evaluated relationships between sex steroid hormone levels in plasma and risk of breast cancer in postmenopausal women by use of a case-control study nested within the Nurses' Health Study. Methods: Blood samples were collected during the period from 1989 through 1990. Among postmenopausal women not using hormone replacement therapy at blood collection (n = 11 169 women), 156 women were diagnosed with breast cancer after blood collection but before June 1, 1994. Two control subjects were selected per case subject and matched with respect to age, menopausal status, month and time of day of blood collection, and fasting status at the time of blood collection. Results: From comparisons of highest and lowest (reference) quartiles, we observed statistically significant positive associations with risk of breast cancer for circulating levels of estradiol (multivariate relative risk [RR] = 1.91; 95% confidence interval [CI] = 1.06-3.46), estrone (multivariate RR = 1.96; 95% CI = 1.05-3.65), estrone sulfate (multivariate RR = 2.25; 95% CI = 1.23- 4.12), and dehydroepiandrosterone sulfate (multivariate RR = 2.15; 95% CI = 1.11-4.17). We found no substantial associations with percent free or percent bioavailable estradiol, androstenedione, testosterone, or dehydroepiandrosterone. The positive relationships were substantially stronger among women with no previous hormone replacement therapy. Conclusion: Our data, in conjunction with past epidemiologic and animal studies, provide strong evidence for a causal relationship between postmenopausal estrogen levels and the risk of breast cancer. [J Natl Cancer Inst 1998;90: 1292-9]Keywords
This publication has 47 references indexed in Scilit:
- Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperaturePublished by Elsevier ,2003
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Insulin‐like growth‐factor‐binding protein 3 is decreased in early‐stage operable pre‐menopausal breast cancerInternational Journal of Cancer, 1995
- Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissuesEuropean Journal of Cancer and Clinical Oncology, 1989
- Flexible regression models with cubic splinesStatistics in Medicine, 1989
- Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal womenEuropean Journal of Cancer and Clinical Oncology, 1986
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986
- Serum Concentrations of Estrone, Androstenedione, Testosterone and Sex-hormone-binding Globulin in Postmenopausal Women with Breast Cancer and in Age-matched ControlsUpsala Journal of Medical Sciences, 1979
- Chromatographic purification of estradiol-17β for use in radio-ligand assayBiochemical Medicine, 1970